Sun Pharma Advanced Research Company Ltd

Sun Pharma Advanced Research Company Ltd (SPARC) has experienced a notable shift in its technical momentum, moving from a bullish to a mildly bullish stance, reflecting a nuanced change in investor sentiment despite a recent decline in share price. This article analyses the latest technical indicators, price movements, and comparative returns against the broader Sensex benchmark to provide a comprehensive view of the stock’s current positioning.

Sun Pharma Advanced Research Company Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 22 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 22 July 2026, providing investors with the latest insights into its performance and outlook.

Sun Pharma Advanced Research Company Ltd (SPARC) has experienced a notable shift in its valuation parameters, moving from a very expensive to an expensive rating. This change, reflected in key metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, signals a recalibration of price attractiveness relative to its historical averages and peer group within the Pharmaceuticals & Biotechnology sector.

Sun Pharma Advanced Research Company Ltd experienced a notable intraday decline on 17 Jul 2026, touching a low of Rs 236.55 as selling pressure intensified. The stock underperformed its sector and broader market indices, reflecting immediate headwinds despite a generally positive market environment.

Sun Pharma Advanced Research Company Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 22 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 11 July 2026, providing investors with the latest insights into its performance and outlook.

The Sensex declined 0.64% on 8 Jul 2026, yet Sun Pharma Advanced Research Company Ltd surged 8.26%, outperforming its Pharmaceuticals & Biotechnology sector by 5.71 percentage points. This sharp single-session gain stands out as a distinctly stock-specific event amid broader market weakness.

With a sustained rally that has propelled Sun Pharma Advanced Research Company Ltd to a fresh 52-week high of Rs 273.5 on 8 Jul 2026, the stock’s momentum is underpinned by a confluence of robust technical indicators and strong price action.

With a sustained seven-day rally culminating in a fresh 52-week high of Rs 272 on 7 Jul 2026, Sun Pharma Advanced Research Company Ltd has demonstrated remarkable price momentum, outpacing its sector and broader market indices.

Surging to an intraday peak of Rs 262.05 on 6 Jul 2026, Sun Pharma Advanced Research Company Ltd has marked a significant milestone by reaching a fresh 52-week high. This rally is underpinned by a confluence of strong technical indicators and sustained price momentum, setting the stock apart in a market where the Sensex has gained a modest 0.53% today.

The Sensex advanced 0.4% on 6 Jul 2026, yet Sun Pharma Advanced Research Company Ltd outpaced the broader market with an 8.43% gain, reaching an intraday high of Rs 259.8. This 8.27 percentage-point outperformance over its Pharmaceuticals & Biotechnology sector peers highlights a distinctly stock-specific rally rather than a market-wide lift.

Sun Pharma Advanced Research Company Ltd (SPARC) has experienced a notable shift in its valuation parameters, moving from an expensive to a very expensive category. This change, reflected in key metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, signals a significant alteration in the stock’s price attractiveness relative to its historical and peer benchmarks.

Sun Pharma Advanced Research Company Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 22 May 2026. While the rating was revised on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 30 June 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Sun Pharma Advanced Research Company Ltd (SPARC) has witnessed a notable shift in its valuation parameters, moving from a very expensive to an expensive rating. This change reflects a recalibration in price attractiveness, driven by significant adjustments in key metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios relative to its historical averages and peer group. Investors are now reassessing the stock’s potential amid evolving market dynamics and sector performance.

Sun Pharma Advanced Research Company Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 22 May 2026. While the rating was revised on that date, the analysis and financial metrics discussed here reflect the company’s current position as of 19 June 2026, providing investors with the latest insights into its performance and outlook.

With a decisive break above Rs 252.95 on 18 Jun 2026, Sun Pharma Advanced Research Company Ltd has reached a new 52-week high, marking a significant milestone in its ongoing price momentum. This surge comes after a sustained five-day rally that has propelled the stock up by over 21% in that period, outpacing its sector by 3.05% on the day.

Sun Pharma Advanced Research Company Ltd (SPARC) has experienced a notable shift in its valuation parameters, moving from an 'expensive' to a 'very expensive' rating. This change, driven by key metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, signals a significant alteration in the stock's price attractiveness relative to its historical averages and peer group within the Pharmaceuticals & Biotechnology sector.

Sun Pharma Advanced Research Company Ltd (SPARC) has experienced a notable shift in price momentum, with technical indicators signalling a transition from mildly bullish to bullish trends. The stock’s recent surge, coupled with upgraded technical grades and a strong Mojo Score, underscores renewed investor interest in this small-cap pharmaceutical player amid a volatile market backdrop.